Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2
Epidemiological and mechanistic studies suggest that some US Food and Drug Administration (FDA)-approved drugs can reduce the incidence of cancer and inhibit tumor growth. Therefore, investigating FDA-approved drugs for cancer chemoprevention is a promising strategy. In this study, we screened FDA-a...
Main Authors: | Lili Zhao, Yuhan Zhang, Ang Li, Xuebo Lu, Mingzhu Li, Qiang Yuan, Ning Yang, Xiaokun Zhao, Xin Li, Yanan Jiang, Kangdong Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S237277052200119X |
Similar Items
-
Azelnidipine may be a valuable drug for chemoprevention of ESCC with high MEK1/2 levels
by: Haili Qian
Published: (2022-12-01) -
Tegaserod Maleate Suppresses the Growth of Gastric Cancer In Vivo and In Vitro by Targeting MEK1/2
by: Zitong Wang, et al.
Published: (2022-07-01) -
Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma
by: Qiang Yuan, et al.
Published: (2024-03-01) -
Cysteine protease inhibitor 1 promotes metastasis by mediating an oxidative phosphorylation/MEK/ERK axis in esophageal squamous carcinoma cancer
by: Liangming Zhang, et al.
Published: (2024-02-01) -
Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
by: Pui-Kei Wu, et al.
Published: (2020-07-01)